| 77 | Parkinson disease |
| 72 | Humans |
| 55 | Nervous system diseases |
| 44 | Male |
| 37 | Female |
| 34 | Aged |
| 31 | Human |
| 28 | Middle Aged |
| 24 | Animals |
| 17 | Parkinson's disease |
| 17 | Adult |
| 13 | Parkinson Disease (physiopathology) |
| 13 | Levodopa |
| 13 | Dyskinesia |
| 12 | Parkinson Disease (genetics) |
| 11 | Treatment |
| 11 | Parkinson Disease (drug therapy) |
| 10 | Parkinson Disease (diagnosis) |
| 10 | Parkinson Disease (complications) |
| 9 | Parkinson Disease (therapy) |
| 9 | Parkinson Disease (pathology) |
| 8 | Parkinson Disease (psychology) |
| 8 | Parkinson Disease (epidemiology) |
| 8 | Mutation |
| 8 | Mice |
| 8 | Dopamine |
| 8 | Brain (metabolism) |
| 8 | Aged, 80 and over |
| 7 | Review |
| 7 | Neuropsychological Tests |
| 7 | Basal ganglion |
| 6 | parkinsonism |
| 6 | Treatment Outcome |
| 6 | Severity of Illness Index |
| 6 | Pathogenesis |
| 6 | Parkinsonism |
| 6 | Parkinson Disease (metabolism) |
| 6 | Encephalon |
| 6 | Deep brain stimulation |
| 6 | Cohort Studies |
| 6 | Cognition |
| 6 | Antiparkinson agent |
| 5 | Subthalamic nucleus |
| 5 | Ropinirole |
| 5 | Phenotype |
| 5 | Mutation (genetics) |
| 5 | Mice, Inbred C57BL |
| 5 | Magnetic Resonance Imaging |
| 5 | Evaluation |
| 5 | Emission tomography |
| 5 | Electroencephalography |
| 5 | Diagnosis |
| 5 | Comparative study |
| 5 | Clinical management |
| 5 | Brain (pathology) |
| 5 | Animal |
| 5 | Animal model |
| 4 | multiple system atrophy |
| 4 | genetics |
| 4 | dystonia |
| 4 | dyskinesia |
| 4 | Ubiquitin-Protein Ligases (genetics) |
| 4 | Sequence Alignment |
| 4 | Risk Factors |
| 4 | Prevalence |
| 4 | Positron |
| 4 | Pedigree |
| 4 | Pathophysiology |
| 4 | Parkinson Disease (etiology) |
| 4 | Nuclear magnetic resonance imaging |
| 4 | Motor control |
| 4 | Molecular Sequence Data |
| 4 | Longitudinal Studies |
| 4 | Huntington disease |
| 4 | Genomics |
| 4 | Gene Expression Regulation |
| 4 | Elderly |
| 4 | Dopamine agonist |
| 4 | Disease Models, Animal |
| 4 | Degeneration |
| 4 | Deep Brain Stimulation (methods) |
| 4 | Decision making |
| 4 | D2 Dopamine receptor |
| 4 | Chemotherapy |
| 4 | Case-Control Studies |
| 4 | Amino Acid Sequence |
| 4 | Alzheimer disease |
| 4 | Age of Onset |
| 3 | rating scales |
| 3 | motor fluctuations |
| 3 | levodopa |
| 3 | clinimetrics |
| 3 | United States |
| 3 | Ubiquitin-Protein Ligases (metabolism) |
| 3 | Ubiquitin-Protein Ligases (chemistry) |
| 3 | Tremor |
| 3 | Time Factors |
| 3 | Surveys and Questionnaires |
| 3 | Speech |
| 3 | Spain |
| 3 | Sensorimotor cortex |
| 3 | Safety |
| 3 | Protein-Serine-Threonine Kinases (genetics) |
| 3 | Protein Conformation |
| 3 | Prognosis |
| 3 | Prediction |
| 3 | Parkinson Disease (diagnostic imaging) |
| 3 | Oscillation |
| 3 | Multiple system atrophy |
| 3 | Multiple System Atrophy (diagnosis) |
| 3 | Models, Molecular |
| 3 | Mitochondria (metabolism) |
| 3 | Lewy Body Disease (genetics) |
| 3 | Levodopa (therapeutic use) |
| 3 | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |
| 3 | Italy |
| 3 | Incidence |
| 3 | Genome-Wide Association Study |
| 3 | Genetics |
| 3 | Genetic disease |
| 3 | Genetic Association Studies |
| 3 | Functional imaging |
| 3 | Familial disease |
| 3 | Exploration |
| 3 | Emotions (physiology) |
| 3 | Electromyography |
| 3 | Dystonia |
| 3 | Double-Blind Method |
| 3 | Double blind study |
| 3 | Dopamine Agents (therapeutic use) |
| 3 | Dementia |
| 3 | Computational Biology |
| 3 | Cognition (physiology) |
| 3 | Canada |
| 3 | Brain (physiopathology) |
| 3 | Apolipoproteins E (genetics) |
| 3 | Antiparkinson Agents (therapeutic use) |
| 3 | Analysis of Variance |
| 3 | Agonist |
| 2 | tau Proteins (genetics) |
| 2 | specificity |
| 2 | sensitivity |
| 2 | progressive supranuclear palsy |
| 2 | prediction |
| 2 | mitochondria |
| 2 | methods: statistical |
| 2 | meta‐analysis |
| 2 | galaxies: dwarf |
| 2 | epidemiology |
| 2 | diagnostic criteria |
| 2 | deep brain stimulation |
| 2 | cosmic microwave background |
| 2 | classification |
| 2 | alpha-Synuclein (metabolism) |
| 2 | alpha-Synuclein (genetics) |
| 2 | Working memory |
| 2 | Woman |
| 2 | Virulence |
| 2 | Uptake |
| 2 | United Kingdom |
| 2 | Uncertainty |
| 2 | Ubiquitin (metabolism) |
| 2 | UPDRS |
| 2 | Transcranial magnetic stimulation |
| 2 | Toxoplasma (pathogenicity) |
| 2 | Toxoplasma (genetics) |
| 2 | Topiramate |
| 2 | Thalamus |
| 2 | Synteny |
| 2 | Symptomatology |
| 2 | Supranuclear ophthalmoplegia |
| 2 | Supranuclear Palsy, Progressive (diagnosis) |
| 2 | Stroke |
| 2 | Speech Perception (physiology) |
| 2 | Specificity |
| 2 | Single photon emission tomography |
| 2 | Sex Factors |
| 2 | Serotonin |
| 2 | Sequence Homology, Amino Acid |
| 2 | Sensitivity |
| 2 | Schizophrenia |
| 2 | Risk |
| 2 | Risk factor |
| 2 | Revision |
| 2 | Retrospective Studies |
| 2 | Reproducibility of Results |
| 2 | Rats |
| 2 | Rat |
| 2 | Radiopharmaceuticals |
| 2 | RNA, Messenger (genetics) |
| 2 | Quality of Life |
| 2 | Psychotropic |
| 2 | Psychiatric Status Rating Scales |
| 2 | Protozoan Proteins (genetics) |
| 2 | Prospective |
| 2 | Prospective Studies |
| 2 | Primates |
| 2 | Prefrontal cortex |
| 2 | Positron emission tomography |
| 2 | Polymorphism, Single Nucleotide |
| 2 | Plasticity |
| 2 | Piperidines (therapeutic use) |
| 2 | Phylogeny |
| 2 | Pedunculopontine Tegmental Nucleus (physiology) |
| 2 | Nootropic agent |
| 2 | Neuroimaging |
| 2 | Nervous System Diseases (diagnosis) |
| 2 | Myelodysplastic syndrome |
| 2 | Multiple System Atrophy (physiopathology) |
| 2 | Multicenter study |
| 2 | Mouse |
| 2 | Motor system disorder |
| 2 | Motor Cortex (physiology) |
| 2 | Monkey |
| 2 | Molecular Targeted Therapy |
| 2 | Models |
| 2 | Modeling |
| 2 | Mice, Transgenic |
| 2 | Mice, Knockout |
| 2 | Memory (physiology) |
| 2 | Medicine |
| 2 | Long term |
| 2 | Lewy body |
| 2 | Levodopa (pharmacology) |
| 2 | Levetiracetam |
| 2 | LRRK2 |
| 2 | Japan |
| 2 | Internet |
| 2 | Information processing |
| 2 | Impulse control disorder |
| 2 | Immunohistochemistry |
| 2 | Identification |
| 2 | Homeostasis |
| 2 | High-Throughput Screening Assays |
| 2 | Haplotypes |
| 2 | Glutamate |
| 2 | Genome, Protozoan |
| 2 | Genetic Variation |
| 2 | Genetic Predisposition to Disease |
| 2 | Genetic Predisposition to Disease (genetics) |
| 2 | Gene Expression Profiling |
| 2 | Galaxy: formation |
| 2 | Gait |
| 2 | Gait Disorders, Neurologic (etiology) |
| 2 | Functional Laterality (physiology) |
| 2 | France |
| 2 | Follow-Up Studies |
| 2 | Fluctuations |
| 2 | Facial Expression |
| 2 | Executive function |
| 2 | Excitability |
| 2 | Evaluation scale |
| 2 | Europe |
| 2 | Etiopathogenesis |
| 2 | Epidemiology |
| 2 | Emotion emotionality |
| 2 | Drug Delivery Systems |
| 2 | Dose-Response Relationship, Drug |
| 2 | Dopaminergic Neurons (metabolism) |
| 2 | Dopamine (metabolism) |
| 2 | Dopa |
| 2 | Dominant character |
| 2 | Disease Progression |
| 2 | Development |
| 2 | Dementia (complications) |
| 2 | Degenerative disease |
| 2 | Deep Brain Stimulation |
| 2 | Databases, Factual (statistics & numerical data) |
| 2 | Cues |
| 2 | Cross-Cultural Comparison |
| 2 | Corpus striatum |
| 2 | Conserved Sequence |
| 2 | Conserved Sequence (genetics) |
| 2 | Complication |
| 2 | Communication |
| 2 | Coherence |
| 2 | Cognition Disorders (etiology) |
| 2 | Coccidiosis (parasitology) |
| 2 | Clinical Trials as Topic |
| 2 | Cerebrovascular disease |
| 2 | Case study |
| 2 | Carrier Proteins (genetics) |
| 2 | Canada (epidemiology) |
| 2 | Blood flow |
| 2 | Behavior |
| 2 | Base Sequence |
| 2 | Axon |
| 2 | Autosomal character |
| 2 | Autopsy |
| 2 | Animal Experimentation (standards) |
| 2 | Aminoacid |
| 2 | Amantadine |
| 2 | Alzheimer Disease (genetics) |
| 2 | Alleles |
| 2 | Algorithms |
| 2 | Age Factors |
| 2 | AMPA receptor |
| 1 | ‘light/mild’ cigarettes |
| 1 | ‘light/mild’ beliefs |
| 1 | μm, Micrometers |
| 1 | β Amyloid protein |
| 1 | xenolith |
| 1 | white matter irregularities with increased signal on T2‐weighted images |
| 1 | wearing‐off |
| 1 | voluntary control |
| 1 | volar pads |
| 1 | vitamin D |
| 1 | visual hallucination |
| 1 | ventriculomegaly |
| 1 | ventricular tachycardia |
| 1 | ventricular fibrillation |
| 1 | venous sinus thrombosis |
| 1 | venous drainage congestion |
| 1 | validity |
| 1 | trunk flexion |
| 1 | trunk extension |
| 1 | tremor |
| 1 | treatment |
| 1 | translational |
| 1 | transfer function |
| 1 | tongue |
| 1 | titanite |
| 1 | time scales |
| 1 | tics |
| 1 | thickened corpus callosum |
| 1 | testate amoebae |
| 1 | taxonomy |
| 1 | tauopathies |
| 1 | tau Proteins (metabolism) |
| 1 | task force |
| 1 | systematic review |
| 1 | sustainability |
| 1 | surveys |
| 1 | subthalamic nucleus |
| 1 | substance abuse |
| 1 | stroke |
| 1 | spawning time |
| 1 | spatial analyses |
| 1 | smell |
| 1 | slow progression |
| 1 | sequencing |
| 1 | self‐injurious behavior |
| 1 | seasonal variation |
| 1 | safety |
| 1 | s, Seconds |
| 1 | ropinirole |
| 1 | reproductive potential |
| 1 | reporting recommendations |
| 1 | reliability |
| 1 | rehabilitation |
| 1 | reevaluation |
| 1 | recruitment |
| 1 | reciprocal altruism |
| 1 | recessive inheritance |
| 1 | rapidly growing cerebellum |
| 1 | quality of life |
| 1 | psychogenic movements |
| 1 | protein production |
| 1 | protein function prediction |
| 1 | protease inhibitors |
| 1 | prominent optic nerve sheaths |
| 1 | prominent Virchow–Robin spaces |
| 1 | progressive posterior fossa crowding |
| 1 | programming |
| 1 | primates |
| 1 | prevention |
| 1 | premutation |
| 1 | potassic magma |
| 1 | positron emission tomography |
| 1 | population structure |
| 1 | population genetics |
| 1 | polymicrogyria |
| 1 | polymerase gamma gene |
| 1 | phylogeography |
| 1 | phenotype |
| 1 | pharmacogenomics |
| 1 | peroxyl radical |
| 1 | peroxy radical |
| 1 | perampanel |
| 1 | peptide |
| 1 | peatlands |
| 1 | partial Mantel test |
| 1 | parameter |
| 1 | paralinguistic aspects of speech |
| 1 | palatal tremor |
| 1 | pain |
| 1 | p120RasGAP |
| 1 | oxidation |
| 1 | overt reading |
| 1 | orolingual |
| 1 | orobulbar features |
| 1 | opioids |
| 1 | onset age |
| 1 | olfaction |
| 1 | obstructive ventriculomegaly |
| 1 | nuclear receptors |
| 1 | non‐motor |
| 1 | neurotoxicity |
| 1 | neuroacanthocytosis |
| 1 | nerve growth factors |
| 1 | naloxone |
| 1 | nA, Nanoamp |
| 1 | myoclonus |
| 1 | motor complications |
| 1 | monazite |
| 1 | molecular systematics |
| 1 | mm, Millimeters |
| 1 | ml, Milliliters |
| 1 | mitochondrial disease |
| 1 | mitochondrial DNA |
| 1 | misleading terms |
| 1 | misconceptions |
| 1 | min, Minutes |
| 1 | microtubule‐associated protein tau |
| 1 | metamorphism |
| 1 | metal ion complexes |
| 1 | meningioma |
| 1 | mass‐media campaign |
| 1 | malformation |
| 1 | macrocyclic ligands |
| 1 | mV, Millivolts |
| 1 | mA, Milliamp |
| 1 | lava |
| 1 | late Quaternary |
| 1 | large‐scale structure of Universe |
| 1 | landscape genetics |
| 1 | labelling change |
| 1 | jaw |
| 1 | isodesmic reaction |
| 1 | introductions |
| 1 | intergalactic medium |
| 1 | intellectual disability |
| 1 | infrared: galaxies |
| 1 | information transfer |
| 1 | i.v., Intravenous |
| 1 | i.m., Intramuscular |
| 1 | homozygosity mapping |
| 1 | hexokinase |
| 1 | hereditary hemorrhagic telangiectasia |
| 1 | hereditary benign telangiectasia |
| 1 | heart failure |
| 1 | health status |
| 1 | head drops |
| 1 | habitat distribution |
| 1 | h, Hour |
| 1 | guidelines |
| 1 | glycolysis |
| 1 | glutamate antagonists |
| 1 | globus pallidus internus |
| 1 | genotype |
| 1 | genome‐wide association |
| 1 | gene‐environment interaction |
| 1 | gene‐disease associations |
| 1 | gamma-Aminobutyric Acid (metabolism) |
| 1 | galaxies: statistics |
| 1 | galaxies: individual: NGC 1275 |
| 1 | galaxies: clusters: general |
| 1 | g, Gram |
| 1 | functional magnetic resonance imaging |
| 1 | frontotemporal dementia with parkinsonism linked to chromosome 17 |
| 1 | frog |
| 1 | fragile X syndrome |
| 1 | focal cortical dysplasia |
| 1 | fluorescent probes |
| 1 | fishery management |
| 1 | fishery effects |
| 1 | fisheries management |
| 1 | fish schools |
| 1 | fetal pads |
| 1 | falling |
| 1 | facial |
| 1 | executive functions |
| 1 | ethics |
| 1 | electrostatic surface analysis |
| 1 | efficacy |
| 1 | effective distance |
| 1 | ecophysiology |
| 1 | dyskinesias |
| 1 | dural venous sinuses |
| 1 | drug efflux transporters |
| 1 | dopamine |
| 1 | disease transmission |
| 1 | dioxins |
| 1 | dinoflagellate cyst |
| 1 | dibenzofurans |
| 1 | diagnosis |
| 1 | depression |
| 1 | dementia |
| 1 | databases |
| 1 | database schema |
| 1 | data model |
| 1 | dark matter |
| 1 | dark ages, reionization, first stars |
| 1 | d-amphetamine |
| 1 | cruelty |
| 1 | cosmology: observations |
| 1 | cosmological parameters |
| 1 | corticobasal degeneration |
| 1 | coprolalia |
| 1 | congenital Chiari I malformation |
